Skip to main content
. 2022 May 17;80:104062. doi: 10.1016/j.ebiom.2022.104062

Figure 1.

Fig 1

Selection of SARS-CoV-2 T- and B-cell polyepitope regions for an improved dendritic cell-targeting vaccine platform. (a) Mapping of selected SARS-CoV-2 epitope-enriched regions. (1) Four selected vaccine regions. (2) Predicted SARS-CoV-2 CD8+ T-cell epitopes (NetMHC 4.0). (3) Described SARS-CoV-2 CD8+ T-cell epitopes at the time of vaccine region selection. (4) Predicted SARS-CoV-2 CD4+ T-cell epitopes (NetMHCII 2.3). (5) Described SARS-CoV-2 CD4+ T-cell epitopes at the time of vaccine region selection. (6) Predicted linear B-cell epitopes (BepiPred 2.0). (7) Described SARS-CoV-2 IgM, IgA, and IgG epitopes at the time of vaccine region selection. (b) Vaccine (v) regions (vS1, vRBD, vS2 and vN2) and control region not included in the vaccine (N1-N2) and (c) CD40.CoV2 vaccine construct.